Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Hypomethylation-mediated upregulation of the WASF2 promoter region correlates with poor clinical outcomes in hepatocellular carcinoma

Fig. 4

WASF2 suppression attenuates HCC tumorigenesis and metastatic in vivo. A Tumor growth in mice injected subcutaneously with Huh-7 cells inactivating WASF2 (n = 6 per group; unpaired t-test). B Mouse images (left) and mass images of xenograft mouse model established with Huh-7 cells transfected with negative control siRNA and siWASF2 (right). The arrows indicate tumor mass. C Box plot of tumor weight in two groups (left) and box plot of WASF2 expression in xenograft tumor tissues assayed using qRT-PCR (right, n = 6 per group; unpaired t-test). D Representative images of H&E and IHC staining for WASF2, Ki-67, Snail, and cleaved caspase-3 in xenograft tumors derived from negative-control siRNA (NC) or siWASF2 transfected Huh-7 cells. Scale bar = 100 μm. E The efficiency of siWASF2 in ras-NIH-3 T3 cells and F body weight among the two groups of mice (n = 5 per group; unpaired t-test). G Representative in vivo images of nodules (arrow) 14 days after injection of transfected ras-transformed NIH-3 T3 cells with negative control siRNA (n = 5) or siWASF2 (n = 5) using a lung metastasis mouse model. H The number of nodules on the surface of the mouse lungs was counted. *P < 0.05; **P < 0.01. Data were shown as mean ± SEM

Back to article page